Page last updated: 2024-10-30

lorazepam and Creutzfeldt-Jakob Syndrome

lorazepam has been researched along with Creutzfeldt-Jakob Syndrome in 1 studies

Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.

Creutzfeldt-Jakob Syndrome: A rare transmissible encephalopathy most prevalent between the ages of 50 and 70 years. Affected individuals may present with sleep disturbances, personality changes, ATAXIA; APHASIA, visual loss, weakness, muscle atrophy, MYOCLONUS, progressive dementia, and death within one year of disease onset. A familial form exhibiting autosomal dominant inheritance and a new variant CJD (potentially associated with ENCEPHALOPATHY, BOVINE SPONGIFORM) have been described. Pathological features include prominent cerebellar and cerebral cortical spongiform degeneration and the presence of PRIONS. (From N Engl J Med, 1998 Dec 31;339(27))

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Rathinakumar, H1
Schutz, C1
Smith, R1
French, BR1
Mhadi, E1
Brandt, K1

Other Studies

1 other study available for lorazepam and Creutzfeldt-Jakob Syndrome

ArticleYear
Creutzfeldt-Jakob disease presenting as catatonia with desaturation on lorazepam challenge.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2022, Volume: 34, Issue:3

    Topics: Catatonia; Creutzfeldt-Jakob Syndrome; Humans; Lorazepam

2022